Cell therapy with placenta-derived mesenchymal stem cells for secondary progressive multiple sclerosis patients in a phase 1 clinical trial.

ABSTRACT: Mesenchymal stem cell (MSC) has attracted significant attention in clinical research due to their immunomodulatory properties and potential to reduce inflammation in autoimmune disorders, such as multiple sclerosis (MS). This study evaluates the safety and feasibility of placenta-derived MSCs (PLMSCs) in five participants with secondary-progressive multiple sclerosis (SPMS). The primary outcomes focused on safety and tolerability, assessed through adverse event monitoring over six months. Secondary exploratory outcomes included clinical, imaging, and immunological measures. Patients underwent baseline evaluations and follow-up assessments comprising cognitive and psychological assessments, expanded disability status scale (EDSS), clinical signs, diffusion tensor imaging (DTI), functional M

SUBMITTER: Shokati A 

PROVIDER: S-EPMC12062319 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature